Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:1330:33-54.
doi: 10.1007/978-3-030-73359-9_3.

Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression

Maureen L Drakes  1 , Patrick J Stiff  2
Affiliations

Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression

Maureen L Drakes et al. Adv Exp Med Biol. 2021.

Abstract

Ovarian cancer generally escapes diagnosis until the advanced stages. High-grade serous ovarian cancer (HGSOC) is the most frequently occurring form of this malaise and is a disease which has the highest mortality rate of gynecologic cancers. Over recent years it has been revealed that the course of such cancers can be significantly influenced by the nature of immune cells in tumors at the time of diagnosis and by immune cells induced by therapy. Numerous investigators have since focused on disease biology to identify biomarkers or therapeutic targets. Yet, while over the past decade there have been significant improvements in state-of-the-art surgery for ovarian cancer as frontline therapy, there have been limited advancements in the development of novel curative or management drugs for this disease. This chapter discusses the major elements of immune suppression in HGSOC from a biological viewpoint, mechanisms of overcoming resistance to therapies, and recent therapy aimed at improving patient care and survival.

Keywords: Dendritic cell vaccine therapy; Epigenetic modulation; Immune checkpoint junctions; Immune suppression; Novel therapies; Ovarian cancer; Tumor microenvironment; Tumor-associated macrophages.

PubMed Disclaimer

References

    1. Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., et al. (2013). Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models. Cancer Cell, 24(6), 751–765. - PubMed - PMC - DOI
    1. Prat, J. (2012). New insights into ovarian cancer pathology. Annals of Oncology, 23(Suppl 10), 111. - DOI
    1. Cole, A. J., Dwight, T., Gill, A. J., Dickson, K. A., Zhu, Y., Clarkson, A., et al. (2016). Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 6, 26191. - PubMed - PMC - DOI
    1. Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609–615. - DOI
    1. Lord, C. J., Tutt, A. N., & Ashworth, A. (2015). Synthetic lethality and cancer therapy: Lessons learned from the development of PARP inhibitors. Annual Review of Medicine, 66, 455–470. - PubMed - DOI - PMC

LinkOut - more resources